Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor?

Tefferi, Ayalew
November 2007
Mayo Clinic Proceedings;Nov2007, Vol. 82 Issue 11, p1316
Academic Journal
The article provides a comprehensive look at current issues regarding the use of erythropoiesis-stimulating agents in patients with chronic renal failure. The U.S. Food and Drug Administration has had safety concerns regarding the use of the drug and has specified a hemoglobin target concentration of 10 to 12 g/dL. According to the author, it is prudent to avoid native erythropoietin therapy in any patient whose pretreatment hemoglobin concentration is 10 g/dL.


Related Articles

  • Earlier epoetin labelling changes expanded by US FDA.  // Reactions Weekly;11/17/2007, Issue 1178, p5 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the revised box warnings and other labelling changes to erythropoietin agonists (epoetins). It says that the new labelling highlights the risks associated with the use of darbepoetin alfa and epoetin alfa in cancer...

  • ESA Dosing Update in CKD.  // Monthly Prescribing Reference;Aug2011, Vol. 27 Issue 8, pA.14 

    The article reports that the U.S. Food and Drug Administration have made three dosage application recommendations in 2011 for erythropoiesis-stimulating agents (ESAs) used in chronic kidney disease (CKD) treatments.

  • Nephrology Nurse Roundtable. Anemia Management: One Protocol Does Not Fit All. Headley, Carol Motes // Nephrology Nursing Journal;Jan/Feb2012, Vol. 39 Issue 1, p63 

    The article discusses the employment of erythropoiesis-stimulating agent (ESA) in management of anemia. It states that treatment of the said condition to a hemoglobin (Hgb) target with ESA, which was once considered as best practice, was changed by the U.S. Food and Drug Administration (FDA). It...

  • Erthyropoietin Stops Chronic Diffuse Transfusion-Dependent Gastrointestinal Bleeding. Zaharia-Czeizler, Veronica // Annals of Internal Medicine;11/20/2001, Vol. 135 Issue 10, p933 

    Examines the benefits of erythropoietin in anemic patient with chronic renal failure. Decline in the bleeding time in uremic patients; Increase in the platelet count; Decrease in protein C, protein S and antithrombin III levels.

  • 393. Hospitalization results in prolonged decrease in Hgb levels and increased Epo requirements. Yaqub, M.S.; Leiser, J.; Molitoris, B.A. // Kidney;May/Jun2002, Vol. 11 Issue 3, p131 

    Provides information on a study which investigated the increase in erythropoietin requirements following hospitalization in end-stage renal disease patients. Methodology; Results; Conclusion.

  • Subcutaneous epoetin alfa: contraindicated in Singapore in chronic kidney disease patients.  // WHO Drug Information;2014, Vol. 28 Issue 1, p22 

    The article reports that the Health Sciences Authority (HSA) has advised that subcutaneous (SC) epoetin alfa is contraindicated in chronic kidney disease patients in Singapore.

  • At Last: FDA Clears AMAG's Feraheme for Anemia.  // Bioworld Week;7/6/2009, Vol. 17 Issue 27, p3 

    The article reports on the approval of AMAG Pharmaceuticals Inc.'s Feraheme by the U.S. Food and Drug Administration for the treatment of anemia in adults with chronic kidney disease. It states that recommended dosage of the drug is 510 milligrams intravenously. As a result of the approval, the...

  • The challenge of chronic renal failure in the developing world: possible use of acacia gum. Al-Mosawi, A. J. // Pediatric Nephrology;May2002, Vol. 17 Issue 5, p390 

    Investigates the use of acacia gum in children with chronic renal failure lacking access to renal replacement therapies. Summary of the effects of gum arabic administration; View of U.S. Food and Drug Administration on gum arabic; Antihypertensive effect in gum arabic.

  • FDA suggests labeling change for low--molecular-weight heparin.  // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p83 

    The article reports on a suggestion by the U.S. Food & Drug Administration (FDA) to Innohep Pharmion LLC, manufacturer of tinzaparin, to revise the labeling for the low-molecular-weight heparin to indicate a potential increased risk of death for renal insufficiency patients aged 70 years and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics